Avalon Prila 5% Topical Anesthetic Cream – 5g
Pigmanorm Cream for Skin Pigmentation & Dark Spots – 30g
Sold More Than 23 Times
Customers also bought
Avalon Prila 5% Topical Anesthetic Cream – 5g
Grenason ointment for hemorrhoids, boils and ulcers
Contractopex Gel 20g
Treatment of Molluscum contagiosum ACM - 3ml
Eucerin 48 Hour Deodorant - 50 ml
Yoko Spa Milk Salt - 300g
Laboratoire ACM Novophane 60 Vegetable Capsules
Now Natural Deodorant with Alum Solid - 120 gmPigmanorm Cream for Skin Pigmentation & Dark Spots – 30g
Struggling with melasma, dark spots, or uneven skin tone affecting your confidence?
Persistent pigmentation often requires a pharmaceutical-grade treatment that targets melanin production at its source.
Pigmanorm Cream by Riyadh Pharma features a powerful triple-action formula designed to reduce pigmentation, calm inflammation, and promote skin cell renewal.
It is commonly used for advanced pigmentation conditions and should be applied under medical guidance.
Key Benefits & Formula:
Helps reduce hyperpigmentation and dark spots
Triple active ingredients targeting melanin production
Reduces inflammation associated with pigmentation
Promotes skin renewal through Tretinoin
Improves skin texture and tone
Pharmaceutical-grade treatment for controlled use
How to Use & Precautions:
Cleanse the skin and gently pat dry
Apply a very small amount (pea-sized or 0.5 cm)
Apply precisely to affected areas only
Use once daily at night, at least 30 minutes before bedtime
Apply a moisturizer one hour after application if dryness occurs
Use sunscreen SPF 30 or higher during daytime
Follow physician instructions regarding duration and frequency
Frequently Asked Questions (FAQ)
Is Pigmanorm safe to use?
Yes, when used correctly and under medical supervision.
Can it be applied to the entire face?
It is recommended to apply only to affected areas.
When will results appear?
Results vary, but improvement is usually seen within a few weeks.
Is it suitable for sensitive skin?
Not recommended without consulting a dermatologist.

